 Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately 34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 GLOBE NEWSWIRE CymaBay Therapeutics, Inc. NASDAQ: CBAY CymaBay or the Company announced today that it has entered into a ... The post CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Sel... 